MorphoSys details product strategy

MorphoSys (NMarkt:MOR) said in addition to its ongoing research service business it is developing proprietary human therapeutic antibodies in inflammation, cancer and infectious diseases. MOR plans to develop the antibodies through Phase II testing and then out license the compounds. The company said it expects to generate one such candidate per year. ...